F. Cervantes

488 total citations
25 papers, 344 citations indexed

About

F. Cervantes is a scholar working on Genetics, Hematology and Oncology. According to data from OpenAlex, F. Cervantes has authored 25 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 12 papers in Hematology and 8 papers in Oncology. Recurrent topics in F. Cervantes's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Acute Myeloid Leukemia Research (5 papers). F. Cervantes is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Acute Myeloid Leukemia Research (5 papers). F. Cervantes collaborates with scholars based in Spain, Italy and United Kingdom. F. Cervantes's co-authors include C Rozmán, Emili Montserrat, Jordi Esteve, Joan Bladé, Francesc Cobo, Emilio Montserrat, Francesc Bosch, Elı́as Campo, Armando López‐Guillermo and Joan Carles Reverter and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

F. Cervantes

22 papers receiving 317 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. Cervantes Spain 11 185 143 137 128 62 25 344
А. М. Ковригина Russia 7 84 0.5× 69 0.5× 93 0.7× 118 0.9× 59 1.0× 145 264
Bjarne Bach Pedersen Denmark 6 124 0.7× 226 1.6× 110 0.8× 55 0.4× 26 0.4× 13 368
Anne Kirsti Blystad Norway 10 77 0.4× 60 0.4× 231 1.7× 185 1.4× 14 0.2× 14 328
R Hoyt Australia 10 90 0.5× 127 0.9× 114 0.8× 89 0.7× 37 0.6× 13 304
Silvia Trappolini Italy 7 42 0.2× 154 1.1× 79 0.6× 48 0.4× 20 0.3× 13 290
Monica V.E. Gallivan United States 9 160 0.9× 208 1.5× 27 0.2× 43 0.3× 32 0.5× 16 346
S Motomura Japan 8 149 0.8× 82 0.6× 209 1.5× 147 1.1× 8 0.1× 14 358
Wanda Knopińska‐Posłuszny Poland 9 65 0.4× 112 0.8× 84 0.6× 93 0.7× 8 0.1× 33 298
Árpád Szomor Hungary 9 67 0.4× 92 0.6× 109 0.8× 82 0.6× 14 0.2× 31 267
J Biggs Australia 5 54 0.3× 171 1.2× 114 0.8× 60 0.5× 60 1.0× 5 309

Countries citing papers authored by F. Cervantes

Since Specialization
Citations

This map shows the geographic impact of F. Cervantes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Cervantes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Cervantes more than expected).

Fields of papers citing papers by F. Cervantes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Cervantes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Cervantes. The network helps show where F. Cervantes may publish in the future.

Co-authorship network of co-authors of F. Cervantes

This figure shows the co-authorship network connecting the top 25 collaborators of F. Cervantes. A scholar is included among the top collaborators of F. Cervantes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Cervantes. F. Cervantes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tapper, William, Joannah Score, Andrew Chase, et al.. (2025). Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22 / CD40. Blood. 146(26). 3228–3233.
2.
Harrison, Claire, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, et al.. (2011). Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF).. Journal of Clinical Oncology. 29(18_suppl). LBA6501–LBA6501. 22 indexed citations
3.
Cervantes, F.. (2005). Myelofibrosis With Myeloid Metaplasia: Diagnosis, Prognostic Factors, and Staging. Seminars in Oncology. 32(4). 395–402. 11 indexed citations
4.
Montoto, Silvia, Armando López‐Guillermo, Albert Altés, et al.. (2004). Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Annals of Oncology. 15(10). 1484–1489. 56 indexed citations
5.
Montoto, Silvia, Armando López‐Guillermo, Ana Ferrer, et al.. (2002). Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Annals of Oncology. 13(4). 523–530. 34 indexed citations
6.
Nadal, E., et al.. (2001). Hypercalcemia as the Presenting Feature of T-Cell Lymphoid Blast Crisis of Ph-Positive Chronic Myeloid Leukemia. Leukemia & lymphoma. 41(1-2). 203–206. 9 indexed citations
7.
Cid, Joan, Álvaro Cervera, F. Cervantes, et al.. (2000). Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia. Annals of Hematology. 79(7). 392–395. 33 indexed citations
8.
Rozmán, C, et al.. (1999). Magnetic resonance imaging in myelofibrosis and essential thrombocythaemia: contribution to differential diagnosis. British Journal of Haematology. 104(3). 574–580. 6 indexed citations
9.
Cervantes, F., et al.. (1998). The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. European Journal Of Haematology. 60(2). 101–105. 39 indexed citations
10.
Cobo, Francesc, F. Cervantes, Carmen Martı́nez, et al.. (1995). Multiple Myeloma Following Essential Thrombocythemia. Leukemia & lymphoma. 20(1-2). 177–179. 11 indexed citations
11.
López‐Guillermo, Armando, Emili Montserrat, Francesc Bosch, et al.. (1994). Low-Grade Lymphoma: Clinical and Prognostic Studies in a Series of 143 Patients from a Single Institution. Leukemia & lymphoma. 15(1-2). 159–165. 21 indexed citations
12.
Terol, María José, Dolors Tàssies, Armando López‐Guillermo, et al.. (1994). [Sepsis by Candida tropicalis in patients with granulocytopenia. A study of 10 cases].. PubMed. 103(15). 579–82. 3 indexed citations
13.
Salgado, Camino, et al.. (1993). [Multiple myeloma after monoclonal gammopathy of uncertain significance. Study of 10 patients].. PubMed. 38(5). 371–4.
14.
Tàssies, Dolors, et al.. (1992). [Behçet's disease with an onset prior to the appearance of chronic myeloid leukemia].. PubMed. 99(2). 67–8. 10 indexed citations
15.
Cervantes, F., Camino Salgado, Evarist Feliú, Emili Montserrat, & C Rozmán. (1991). Interferon alpha-2b for Essential Thrombocythaemia: Results in 13 Previously Untreated Patients. Leukemia & lymphoma. 4(5-6). 351–354. 2 indexed citations
16.
Cervantes, F., et al.. (1990). Bone marrow histopathology in primary myelofibrosis: Clinical and haematologic correlations and prognostic evaluation. European Journal Of Haematology. 44(2). 95–99. 30 indexed citations
17.
Cervantes, F., et al.. (1990). [Blast crisis of chronic myeloid leukemia with positive Philadelphia chromosome: course and clinico-hematologic profile in 80 patients].. PubMed. 94(18). 681–4. 1 indexed citations
18.
Cervantes, F., Joan Carles Reverter, Emili Montserrat, & C Rozmán. (1986). Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide, and prednimustine.. PubMed. 70(5). 665–7. 22 indexed citations
19.
Ribera, Josep‐María, Enric Carreras, F. Cervantes, Evarist Feliú, & C Rozmán. (1985). [Hodgkin's disease with cutaneous fistulization of the adenopathies].. PubMed. 30(1). 61–2. 1 indexed citations
20.
Feliú, Evarist, F. Cervantes, Joan Bladé, & C Rozmán. (1980). Thrombocytosis in Quiescent Chronic Granulocytic Leukaemia after Vincristine and 6-Mercaptopurine Therapy. Acta Haematologica. 64(4). 224–226. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by А. М. Ковригина Breakdown of academic impact, for papers by Bjarne Bach Pedersen Breakdown of academic impact, for papers by Anne Kirsti Blystad Breakdown of academic impact, for papers by R Hoyt Breakdown of academic impact, for papers by Silvia Trappolini Breakdown of academic impact, for papers by Monica V.E. Gallivan Breakdown of academic impact, for papers by S Motomura Breakdown of academic impact, for papers by Wanda Knopińska‐Posłuszny Breakdown of academic impact, for papers by Árpád Szomor Breakdown of academic impact, for papers by J Biggs
Rankless by CCL
2026